There’s been a lot of discussion around pricing for specialty drugs, payor pushback and how it impacts investors. Roberto Bellini highlights some of the important themes to watch. ########## (By Roberto Bellini)

The challenges surrounding public reimbursement for companies developing rare disease drugs. ########## (By Joanne Koskie and Christine Beyaert)

Whether diagnostic and personalized medicine technologies can be patented has been hotly debated in a number of jurisdictions. Court challenges recently launched in Canada bring the controversy to our backyard. ########## (By Carmela DeLuca and Katherine Bonter)